Observational studyArthritis care & research2025
Association Between Metabolic Syndrome and Radiographic Changes in Psoriatic Arthritis: A Cohort Study.
Observational study in Arthritis care & research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unravelling Fibromyalgia in Psoriatic Arthritis.Rheumatology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveMetabolic syndrome (MetS) is a known comorbidity of psoriatic arthritis (PsA) and is associated with PsA disease activity. We aimed to explore the association between MetS and radiographic features (peripheral and axial) in PsA.
methodsWe included patients with PsA followed at our prospective observational cohort for the period between 1978 and 2024. We identified patients with MetS on longitudinal follow-up and used generalized estimating equations (GEE) analysis to define the radiographic features independently associated with MetS, adjusting for age, sex, PsA disease duration, calendar decade, and use of targeted disease-modifying antirheumatic drugs.
resultsThe study population consisted of 1,422 patients, out of which 400 (28.1%) had MetS at baseline (clinic entry) and 836 (58.79%) had a record of MetS (per the harmonized definition) over a median follow-up duration of 10.59 (interquartile range 4.52-18.28) years. The mean (SD) age of our cohort at baseline was 44.43 (12.98) years, with 789 patients (55.5%) identifying as men. Mean (SD) body mass index was 28.79 (6.36) kg/m
conclusionMetS is associated with degenerative and metabolic changes in the spine and entheses but not with radiographic damage in PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.